Open Access

Corticosteroids influence the mortality and morbidity of acute critical illness

  • Mohamed Y Rady1Email author,
  • Daniel J Johnson1, 2,
  • Bhavesh Patel1,
  • Joel Larson1 and
  • Richard Helmers1
Critical Care200610:R101

https://doi.org/10.1186/cc4971

Received: 18 April 2006

Accepted: 26 June 2006

Published: 17 July 2006

Abstract

Introduction

Use of corticosteroids for adrenal supplementation and attenuation of the inflammatory and immune response is widespread in acute critical illness. The study hypothesis was that exposure to corticosteroids influences the mortality and morbidity in acute critical illness.

Methods

This case–control retrospective study was performed in a single multidisciplinary intensive care unit at a tertiary care institution and consisted of 10,285 critically ill patients admitted between 1 January 1999 and 31 December 2004. Demographics, comorbidities, acute illness characteristics including severity measured by Sequential Organ Failure Assessment, concurrent medications, therapeutic interventions and incidence of infections were obtained from electronic medical records, were examined with multiple regression analysis and were adjusted for propensity of corticosteroid exposure. The primary outcome was hospital death, and the secondary outcome was transfer to a care facility at hospital discharge.

Results

Corticosteroid exposure in 2,632 (26%) patients was characterized by younger age, more females, higher Charlson comorbidity and maximal daily Sequential Organ Failure Assessment scores compared with control patients. Corticosteroids potentiated metabolic and neuromuscular sequels of critical illness with increased requirements for diuretics, insulin, protracted weaning from mechanical ventilation, need for tracheostomy and discharge to a care facility. Early exposure to corticosteroids predisposed to recurrent and late onset of polymicrobial and fungal hospital-acquired infections. Corticosteroids increased the risk for death or disability after adjustments for comorbidities and acute illness characteristics.

Conclusion

Corticosteroids increased the risk for death or disability in critical illness. Hospital-acquired infections and metabolic and neuromuscular sequels of critical illness were exacerbated by corticosteroids. Careful appraisal of the indications for use of corticosteroids is necessary to balance the benefits and risks from exposure in acute critical illness.

Introduction

Administration of corticosteroids in a variety of settings in acute critical illness has become widespread. Corticosteroids are used therapeutically for relative adrenal insufficiency as well as for the attenuation of the inflammatory and immune response in the critically ill [1]. Early use of corticosteroids has been recommended in sepsis, acute lung injury, acute respiratory distress syndrome and refractory vasodilatory shock [25]. The Corticosteroid Randomization after Significant Head Injury study, a large, international, randomized placebo-controlled trial, was terminated after enrolment of 10,000 patients because of an unexpected rise in the death rate after early administration of corticosteroids [6]. That study report raised concerns with regard to the safety of corticosteroids since, up to that time, they had been liberally administered in a variety of life-threatening illnesses with the intent to improve survival. These concerns were substantiated when we observed, in a previous study, that administration of corticosteroids increased the mortality in vasopressor-dependent critical illness [7]. A similar observation of an unexpected increase in mortality from corticosteroids use was also reported from a randomized controlled trial of corticosteroids in late acute respiratory distress syndrome [8].

The morbidity related to metabolic, immune and musculoskeletal side-effects of corticosteroids in noncritical illness has been recognized and has created great interest in developing alternative treatments to avoid these complications. In transplantation practice, the therapeutic use of corticosteroids for immunosuppression has decreased because of the introduction of other therapies targeted against specific cytokines including tumour necrosis factor and interleukins or selective lymphocytes calcineurin inhibition [9, 10]. New immunosuppression regimes produced superior allograft survival and yet had fewer side effects than traditional high-dose corticosteroids [11, 12]. For autoimmune inflammatory disorders and rheumatologic diseases, the use of corticosteroids has also declined because of better treatment options targeting inflammatory cytokines known to influence the progression of these conditions [1316].

The use of corticosteroids in noncritical illness has gradually diminished, yet their use in acute critical illness appears to be expanding in relative adrenal insufficiency, sepsis and systemic inflammatory organ injury. This study was designed to address the following questions: What are the frequency and patient characteristics associated with corticosteroid use in acute critical illness? Does the exposure to corticosteroids influence death or disability? What were the mechanisms for the observed effects of corticosteroids in acute critical illness? This study was a retrospective case–control analysis of all admissions to an adult intensive care unit (ICU) with exposure to corticosteroids defining the case group.

Patients and methods

Study population

The study was granted approval and exemption by the Mayo Foundation Institutional Review Board. The study was performed at Mayo Clinic Hospital, a 220-bed hospital. Patients (≥ 18 years old) were admitted to a closed, 20-bed, multidisciplinary ICU (medical, surgical and coronary care) between January 1999 and December 2004.

Data collection

The patient demographics, comorbidities, type of admission, therapeutic interventions, acute diagnosis and disposition at hospital discharge were obtained from electronic medical records, which were interfaced into an institutional replicated database and extracted electronically [17]. The initial admission was designated as the index admission for those patients with multiple hospital admissions during the six years. Comorbidities were determined by Romano and colleagues' criteria to calculate the Charlson comorbidity score [18]. Diagnoses recorded for the index admission were used to develop the acute hospital diagnosis categories [17]. The severity of illness in the ICU was determined by the Sequential Organ Failure Assessment score, calculated based on the graded severity of dysfunction of six organ systems: neurological, pulmonary, cardiovascular, hepatic, renal and coagulation [19, 20]. The length of stay and time intervals were calculated in hours and then expressed as fractions of days. Hospital discharge to acute, subacute or long-term nursing care, to inpatient rehabilitation, to long-term ventilation or to other types of extended care facilities was utilized as a surrogate marker for disability.

Medication

All medication given during the hospital stay was tracked by the pharmacy database in LastWord 4.1 for Windows (IDX Systems Corp., Burlington, VT, USA), which recorded the date and time of administration, the dose administered and the route of administration. Catecholamine infusion included norepinephrine, phenylephrine, epinephrine, dopamine, dobutamine or milrinone. Exposure to corticosteroids was defined as either via intravenous or enteral administration routes. The total cumulative doses of corticosteroids were calculated during the entire hospital stay and are expressed as hydrocortisone equivalents according to the glucocorticoid effect.

Microbiology and diagnosis of infections

Microbiological cultures were obtained to confirm infection based on established clinical criteria. First, the development of vasodilatory shock: persistent hypotension (mean arterial pressure ≤ 60 mmHg) after adequate volume resuscitation to a central venous pressure between 12 and 15 mmHg [21] and requiring initiation of vasopressor therapy for greater than 24 hours. The second criterion was the presence of two or more of the following criteria for systemic inflammatory response syndrome: temperature >38.5°C or <35.6°C, white cell count >11,000 cells/mm3 or <4,000 cells/mm3, immature neutrophils (bands) >10%, respiratory rate >20/minute, PaCO2 <35 mmHg or requirement for mechanical ventilation, and heart rate >90/minute [22]. Third was the presence of unexplained acute organ dysfunction not due to underlying disease or medications: confusion, restlessness, altered mental status (acute change from baseline) or oliguria. The final criterion was initiation of empiric antibiotics therapy.

The dates and times of cultures performed, including the specimen source, microscopic examination and the semiquantitative organism count, were stored in an electronic database in LastWord 4.1 for Windows (IDX Systems Corp.). Infection was confirmed by the following: the presence of polymorph nuclear cells in normally sterile body fluid; a culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for pathogenic microorganisms; and a focus of infection identified by visual inspection (such as, bowel perforation with content at time of surgery, wound with purulent discharge, pulmonary consolidation on thoracic imaging).

Microorganism growth quantified as 2+ or >15 colony-forming units were considered clinically significant. The date and time of hospital admission was considered the reference time point for each patient to determine the temporal characteristics of infection episodes documented during the hospital stay. Hospital-acquired infection was defined as a new episode of infection developing >48 hours from hospital admission. Recurrent infection was indicated by two or more episodes of infections with different microorganisms at separate times during a hospital stay. Polymicrobial infection was defined as the presence of two or more types of microorganisms from a single location of infection at the same time.

Statistical analysis

Corticosteroid exposure during the hospital stay defined the case group versus the control group. Analysis was performed with Student's t test or Wilcoxon's rank sum test when appropriate. Categorical variables were analysed by chi-square test or Fisher's exact test as appropriate. A nonparametric test of the median (number of points above the median) was performed where appropriate for comparison of the length of stay. For group comparison, the exact P values were reported for each comparison, and Bonferroni correction was applied because of multiple comparisons so that P < 0.001 was considered statistically significant between groups.

Preadmission comorbidities, age, sex, type of admission, use of catecholamines, and respiratory and neurological diagnosis were included in a logistic model to calculate the propensity score (the probability for exposure to corticosteroids) for each study patient. The propensity score was included as a covariate in multiple regression analysis for the primary outcome endpoint, death while in the hospital (hospital death), and for the secondary outcome endpoint, discharge to a care facility (disability). The likelihood ratio test determined the cut-off value for the maximal daily Sequential Organ Failure Assessment score.

Stepwise multiple logistic regressions were performed on three groups of predictors: preadmission comorbidities, type of admission with hospital and intensive care, and hospital diagnosis category. All factors that were significant at P < 0.1 from each group were entered into the final logistic models. Calibration of the final logistic models was examined by Hosmer-Lemeshow goodness-of-fit. Discrimination of the logistic models was examined by the area under the receiver operating characteristic curve.

All statistical tests were two-tailed and significance was accepted at P < 0.05. Statistical analysis was performed using JMP Statistical software (version 5.1; SAS Institute Inc., Cary, NC, USA).

Results

Cohort description

There were 10,258 patients admitted to the ICU, 2,632 (26%) of whom received corticosteroids. Patients receiving corticosteroids were more likely to be younger and female (Table 1). Liver disease, malignancy, chronic obstructive or restrictive pulmonary disease, connective tissue disease and cachexia were more frequent comorbidities in patients who received corticosteroids and were reflected by a higher Charlson Comorbidity score than in control patients. Relative adrenal insufficiency or anti-inflammatory action constituted the majority of indications for corticosteroid use (Table 1). The frequency of medical admissions in the corticosteroid exposure group was higher than the control group (Table 1).
Table 1

Preadmission comorbidities and types admission of the study cohort

 

Control group (n = 7,626)

Corticosteroid exposure group (n = 2,632)

P

Age (years)

72 (48–84)

67 (43–82)

0.0001

Female

2,860 (38)

1,147 (44)

0.0001

Body mass index (kg/m2)

26 (20–35)

26 (20–35)

0.8

Peripheral arterial disease

777 (10)

221 (8)

0.008

Cerebral vascular disease

159 (2)

23 (1)

0.0001

Neurological disease (degenerative brain disease)

1,048 (14)

396 (15)

0.1

Congestive heart failure

974 (13)

361 (14)

0.2

Hypertension

3,687 (48)

995 (38)

0.0001

Diabetes mellitus

1,359 (18)

436 (17)

0.1

Liver disease

636 (8)

351 (13)

0.0001

Malignancy

1,179 (15)

685 (26)

0.0001

Chronic obstructive pulmonary disease

870 (11)

565 (21)

0.0001

Pulmonary disease (restrictive and obstructive)

1,025 (13)

663 (25)

0.0001

Renal disease

577 (8)

223 (8)

0.9

Connective tissue disease

88 (1)

197 (7)

0.0001

Cachexia

157 (2)

126 (5)

0.0001

Charlson comorbidity score

1 (0–4)

2 (0–5)

0.0001

Indications for corticosteroids

   

   Relative adrenal insufficiency

-

1,022 (39)

-

   Anti-inflammatory action

-

1,270 (48)

-

   Immunosuppression

-

340 (13)

-

Types of admission

   

   Coronary care unit

1,561 (20)

211 (8)

0.0001

   Medical

2,623 (34)

1,168 (44)

0.0001

   Surgical

3,442 (46)

1,253 (48)

0.1

Data presented as median (10–90% percentiles) or actual numbers (percentage).

Corticosteroid exposure and hospital care and intensive care

The maximal daily Sequential Organ Failure Assessment score and also the requirement for mechanical ventilation and mechanical ventilation ≥ 96 hours were higher in patients with corticosteroid exposure. The need for tracheotomy was also higher in these patients with a longer stay in the ICU than in control patients. The first dose of corticosteroids was administered early, and in 90% of patients within 4 days from hospital admission (Table 2). The median exposure time to corticosteroids was 3 days at a median total dose of 900 mg hydrocortisone equivalent (Table 2). Catecholamine infusions, antibacterial, antifungal, diuretics, insulin and proton pump inhibitors or histamine-2 blockers were frequent concurrent medications in patients who received corticosteroids compared with control individuals (Table 2).
Table 2

Acute illness characteristics including hospital care, intensive care and outcome for the study cohort

 

Control group (n = 7,626)

Corticosteroid exposure group (n = 2,632)

P

Hospital and intensive care

   

   Maximal daily Sequential Organ Failure Assessment

3 (0–9)

4 (1–11)

0.0001

   Mechanical ventilation

1,889 (25)

765 (29)

0.0001

   Mechanical ventilation ≥ 96 hours

297 (4)

372 (14)

0.0001

   Tracheostomy

124 (2)

204 (8)

0.0001

   Intensive care stay (days)

1.2 (0.2–4.6)

1.9 (0.3–9.6)

0.0001

   Hospital stay (days)

5.1 (1.3–12.4)

6.8 (2.0–19.0)

0.0001

Corticosteroid exposure

   

   Hydrocortisone

0

293 (11)

 

   Dexamethasone

0

783 (30)

 

   Methyl prednisone or prednisone

0

1,556 (59)

 

   Start day of corticosteroids

0

0 (0–4)

 

   Corticosteroid exposure time (days)

0

3 (1–13)

 

   Total hydrocortisone equivalent (mg)

0

900 (100–6,600)

 

Concurrent medication

   

   Catecholamine infusions

2,973 (39)

1,291 (49)

0.0001

   Antibacterial antibiotics

5,217 (68)

2,318 (88)

0.0001

   Antifungal antibiotics

419 (5)

557 (21)

0.0001

   Diuretics

4,360 (57)

1,702 (65)

0.0001

   Insulin

2,424 (32)

1,266 (48)

0.0001

   Proton pump inhibitors or Histamin-2 blockade

5,142 (67)

2,205 (84)

0.0001

Hospital diagnosis category

   

   Cardiovascular

2,348 (31)

790 (30)

0.5

   Respiratory

1,346 (18)

774 (29)

0.0001

   Neurological

876 (11)

440 (17)

0.0001

   Fluid and electrolytes abnormalities

1,504 (20)

694 (26)

0.0001

   Postoperative complications

856 (11)

406 (15)

0.0001

   Gastrointestinal

1,023 (13)

381 (14)

0.2

   Acute renal failure

375 (5)

265 (10)

0.0001

Hospital outcome

   

   Hospital death

327 (4)

261 (10)

0.0001

   Discharge to a care facility

1,562 (20)

762 (29)

0.0001

Data presented as median (10–90% percentiles) or actual numbers (percentage).

Respiratory, neurological, fluid and electrolyte abnormalities, postoperative complications and acute renal failure were more frequent categories of hospital diagnosis in patients exposed to corticosteroids than in the control group. These patients had a longer hospital stay and a higher frequency of death or discharge to a care facility than the control group (Table 2). Hospital death rates were similar for the three groups of indications for corticosteroids: relative adrenal insufficiency, 109 patients (11%); anti-inflammatory effects, 126 patients (10%); and immunosuppression, 26 patients (8%) (P = 0.2).

Corticosteroids and infectious complications and clinical outcome

Corticosteroid exposure in patients was associated with more frequent microbiological cultures with a positive yield than in the control group (Table 3). Corticosteroids were associated with higher frequencies of infection at pulmonary, vascular catheter and central nervous system locations than in the control group (Table 3). Hospital-acquired infections (infection episode >2 days after admission) and recurrent infections (two or more infection episodes during a hospital stay) were more frequent after corticosteroid exposure. Late onset of infection (day of last infection episode during a hospital stay) was also observed in that group (Table 3). Fungal and polymicrobial microorganisms were more likely to be present in patients exposed to corticosteroids (Table 3).
Table 3

Microbiological characteristics of the study cohort

 

Control group (n = 7,626)

Corticosteroid exposure group (n = 2,632)

P

Microbiology

   

   Number of patients with cultures

3,185 (42)

1,764 (67)

0.0001

   Infection confirmed

1,785 (23)

1,215 (46)

0.0001

Location of infection

n = 1,785

n = 1,215

 

   Pulmonary

578 (32)

489 (40)

0.0001

   Abdomen

197 (11)

147 (12)

0.4

   Genital–urinary tract

703 (39)

425 (35)

0.02

   Bloodstream

500 (28)

376 (31)

0.09

   Soft tissue

165 (9)

90 (7)

0.08

   Vascular catheters

156 (9)

158 (13)

0.0002

   Skeletal

54 (3)

24 (2)

0.08

   Central nervous system

46 (3)

47 (4)

0.05

   Head and neck

17 (1)

21 (2)

0.07

   Other

16 (1)

9 (1)

0.7

Temporal characteristics

n = 1,785

n = 1,215

 

   Infection episode ≤ 2 days after admission

1,228 (69)

820 (67)

0.5

   Infection episode >2 days after admission

883 (49)

669 (55)

0.003

   Recurrent infectiona

633 (35)

521 (43)

0.0001

   Day of last infection episode during a hospital stay

2 (0–13)

3 (0–19)

0.003

   Interval between first and last infection episodes (days)

0 (0–10)

0 (0–15)

0.0001

   Interval between first and last infection episodes >2 days

434 (24)

402 (33)

0.0001

Types of microorganisms (culture or microscopy)

n = 1,785

n = 1,215

 

   Bacterial

   

Gram-positive cocci

1,255 (70)

903 (74)

0.02

Gram-negative bacilli

744 (42)

487 (40)

0.4

Other types of bacillib

299 (17)

221 (18)

0.3

Anaerobesc

182 (10)

112 (9)

0.4

Gram-negative cocci

66 (4)

38 (3)

0.4

   Fungal

404(23)

508 (42)

0.0001

Number of types of microorganisms per location

1 (1–4)

2 (1–6)

0.0001

   Polymicrobial infectiond

838 (47)

683 (56)

0.0001

Data presented as median (10–90% percentiles) or actual numbers (percentage). Cultures included blood, sputum, urine, normally sterile body fluid or tissue. aTwo or more infection episodes during a hospital stay. blisteria, Corynebacteria, Actinomyces, bacilli Sp., Legionella and Mycobacterial species; cClostridia, Bacteroids, Peptostreptococci, and Peptococci species.. dTwo or more types of organisms present at the same location site of infection.

Exposure to any type of corticosteroids increased the adjusted risk for hospital death (Table 4). Exposure to corticosteroids with a total hydrocortisone equivalent >900 mg increased the adjusted risk for hospital discharge to a care facility (Table 4).
Table 4

Multiple regression analysis of factors predicting hospital death and discharge to a care facility

 

Wald chi-square

Odds ratio (95% confidence interval)

P

Hospital death a

   

Preadmission comorbidities

   

   Age per decade

22

3.2 (1.9–5.6)

<0.0001

   Female

6

1.3 (1.0–1.5)

0.0176

   Malignancy

18

1.7 (1.3–2.2)

<0.0001

Hospital and intensive care

   

   Medical admission

112

3.2 (2.6–3.9)

<0.0001

   Mechanical ventilation

74

2.6 (2.1–3.2)

<0.0001

   Maximal daily Sequential Organ Failure Assessment score >8

136

3.8 (3.0–4.8)

<0.0001

   Corticosteroid exposure (hydrocortisone, dexamethasone, methyl prednisone or prednisone)

11

1.4 (1.1–1.7)

0.001

Hospital diagnosis category

   

   Acute renal failure

81

3.0 (2.4–3.9)

<0.0001

   Cardiovascular

62

2.2 (1.8–2.7)

<0.0001

   Neurological

69

2.6 (2.1–3.3)

<0.0001

   Respiratory

16

1.5 (1.2–1.8)

<0.0001

Discharge to care facility b

   

Preadmission comorbidities

   

   Age per decade

137

7.9 (5.6–11.1)

<0.0001

   Female

19

1.3 (1.1–1.4)

<0.0001

   Cerebral vascular disease

24

1.6 (1.3–2.0)

<0.0001

   Degenerative brain disease

212

2.7 (2.3–3.0)

<0.0001

   Congestive heart failure

13

1.3 (1.1–1.5)

0.00040

   Chronic obstructive pulmonary disease

4

1.1 (0.9–1.3)

0.05880

   Cachexia

11

1.6 (1.2–2.1)

0.00040

   Diabetes mellitus

6

1.2 (1.0–1.4)

0.01

Hospital and intensive care

   

   Medical admission

118

1.9 (1.7–2.1)

<0.0001

   Corticosteroid exposure

   

Total hydrocortisone equivalent >900 mg

6

1.2 (1.0–1.4)

0.01

Maximal daily Sequential Organ Failure Assessment score ≥ 4

21

1.3 (1.2–1.5)

<0.0001

   Hospital-acquired infection

124

2.2 (1.9–2.6)

<0.0001

   Antifungal antibiotics

10

1.3 (1.1–1.6)

0.00160

   Tracheostomy

63

2.9 (2.3–3.8)

<0.0001

Hospital diagnosis category

   

   Neurological

57

1.7 (1.5–2.0)

<0.0001

   Respiratory

10

1.2 (1.1–1.4)

0.00200

   Postoperative complications

28

1.5 (1.3–1.7)

<0.0001

   Fluid and electrolyte abnormalities

13

1.2 (1.1–1.4)

0.00030

aThe calibration of the multiple logistic model (lack of fit P = 0.9) and discrimination characteristic (area under the receiver operating characteristic curve = 0.88); P < 0.01 for all predictive factors. bThe calibration of the multiple logistic model (lack of fit P = 0.9) and discrimination characteristic (area under the receiver operating characteristic curve = 0.76); P < 0.01 for all predictive factors.

Discussion

The study salient findings were as follows. First, exposure to corticosteroids occurred in 26% of intensive care patients. Many of these patients were already suffering from long-standing comorbidities. A third finding was that corticosteroids increased the risk of death or disability at hospital discharge after adjustment for comorbidities and acute illness characteristics. Finally, early corticosteroid administration exacerbated infectious, metabolic and neuromuscular complications in acute critical illness.

Infectious complications and mortality after corticosteroids

The study observed that corticosteroids increased the risk for hospital death after considering the confounding effects of comorbidities, the diverse nature and severity of the acute illness and therapeutic interventions in the critically ill. The Corticosteroid Randomization after Significant Head Injury study reported similar findings that early exposure to corticosteroids increased mortality two weeks later [6]. The reason for the observed increase in mortality could not be determined in that study; however, in the present study we identified infectious, metabolic and neuromuscular consequences seen in critical illness that were potentiated by corticosteroids and could explain the higher mortality.

While the anti-inflammatory actions could explain the desirable effects of corticosteroids in acute respiratory distress syndrome, septic shock and autoimmune-mediated organ injury, the same actions could also hinder normal host defence mechanisms to overcome and recover from acute infections. We observed that infectious complications related to corticosteroids had distinctive temporal patterns, locations and microbiology characteristics.

The study found that early exposure to corticosteroids predisposed to late development of hospital-acquired infections, with host-borne microorganisms often seen at sites of invasive instrumentation in critical illness such as pulmonary and vascular access sites. Invasive instrumentation at these sites was necessary because of prolonged intensive care and hospital stays in these patients, which increased their vulnerability to recurrent infections. Corticosteroid exposure encouraged polymicrobial and fungal infections. Our observation concurred with previous findings that the use of corticosteroids increased the incidence of fungal superinfections and contributed to higher mortality in the critically ill [23]. In the present study, the late development of infections during hospital stay also explained the high mortality attributed to corticosteroids. Late onset of sepsis from hospital-acquired infection has been associated with a much higher mortality than sepsis related to infection seen early after hospital admission [24].

Our data suggest that corticosteroids increased the incidence of pulmonary infections. The concurrent use of gastric acid suppression with histamine receptor blockade or proton pump inhibitors, prolonged invasive mechanical ventilation and the use of tracheostomy could have predisposed the study patients to frequent pulmonary infections. Patients treated with corticosteroids were also sicker and therefore required gastric acid suppression more commonly and for a longer time than those not treated.

An interesting finding of the study was the trend for administration of corticosteroids, in particular dexamethasone, to patients with central nervous system infections. Early administration of dexamethasone in adults with acute bacterial meningitis had been recommended in order to suppress leptomeningeal inflammations with the aim of decreasing the mortality and neurological sequelae triggered by this type of infection [25]. We did not observe either a mortality reduction or a better functional recovery linked to corticosteroids use in our study. To the contrary, our data suggested that exposure to corticosteroids was an independent factor to increase the risk for death or disability in the presence of a neurological diagnosis (Table 4).

Metabolic and neuromuscular sequels of corticosteroids

Corticosteroids exacerbated several metabolic abnormalities induced by acute critical illness. The mineralocorticoid activity of the administered corticosteroids aggravated fluid retention and interstitial oedema in the critically ill. We observed that diuretics were concurrently administered in 65% of patients already on corticosteroids. The simultaneous use of corticosteroids and diuretics to overcome fluid retention was responsible for frequent electrolyte abnormalities in these patients.

Our study observed that the frequency of insulin use for glycaemic control increased with corticosteroid exposure. Administration of insulin with poor glycaemic control could explain the higher mortality related to corticosteroids in our patients. In a previous study, we reported that the use of corticosteroids influenced glucose metabolism, resulting in poor glycaemic control and insulin resistance in the critically ill [26]. The control of blood glucose in acute critical illness has been recommended to improve clinical outcome [27]. Excessive insulin use with poor glycaemic control has been linked to an increased mortality in both medical and surgical critical illness [26, 28].

A variety of neuromyopathy disorders have been attributed to corticosteroid use in critical illness that delayed the functional recovery of survivors [29, 30]. The present study observed that corticosteroids delayed weaning from mechanical ventilation and increased the need for tracheostomy. The incidence of care dependency and disability requiring discharge to a care facility was also high in these patients. Global and flaccid muscle weakness affecting the limb musculature, truncal musculature and respiratory musculature related to necrotizing myopathy have been reported with corticosteroid use in critical illness [3134]. Delayed recovery of respiratory neuromuscular function and extremity neuromuscular function has been documented because peripheral nerve abnormalities and skeletal muscle abnormalities persisted for years, raising concerns for irreversible neuromuscular dysfunction related to corticosteroid use in critical illness [34, 35].

Corticosteroids increased the frequency of postoperative complications in surgical critical illness. Poor or delayed tissue healing, metabolic abnormalities and hospital-acquired infections could explain the vulnerability to complications after surgical procedures in these patients.

Study limitations

This study was retrospective and performed at a single tertiary care ICU. The patient case mix, the spectrum of comorbidities and hospital care had confounding effects on both the mortality and morbidity observed in this study, and therefore could limit extrapolation of the findings to other practice settings. The study could not define clinical benefit or indications for use of corticosteroids in these patients because of the non-intervention design. The total cumulative dose of corticosteroids given during the hospital stay did not take into account exposure to corticosteroids before hospital admission, which could influence the relationship with clinical outcome. The multivariable analysis had major limitations since unmeasured significant confounding factors might not have been taken into account in this study. Transfer to a care facility was utilized as a measure of delayed recovery and significant disability at hospital discharge. That type of evaluation could have missed the disabilities suffered by survivors who were discharged home, and therefore the reported magnitude of the effect of corticosteroids on disability would have been underestimated.

Conclusion

Corticosteroids increase the risk for death or disability in acute critical illness. Early exposure to corticosteroids increases the frequency of late hospital acquired infections, polymicrobial infections and fungal infections during the hospital stay. Corticosteroids exacerbate metabolic and neuromuscular sequels of critical illness. Careful appraisal of the indications for use of corticosteroids is necessary to balance the benefits and risks from exposure in acute critical illness.

Key messages

  • Corticosteroids increased the risk for death or disability in critical illness.

  • Corticosteroids exacerbated hospital-acquired infections, and metabolic and neuromuscular sequels of critical illness.

  • Careful appraisal of the indications for corticosteroids use in critical illness is necessary to balance the benefits and risks from exposure.

Abbreviations

ICU: 

= intensive care unit.

Declarations

Authors’ Affiliations

(1)
Department of Critical Care Medicine, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Mayo Clinic
(2)
Department of Surgery, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Mayo Clinic

References

  1. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 2005, 353: 1711-1723. 10.1056/NEJMra050541View ArticlePubMedGoogle Scholar
  2. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288: 862-871. 10.1001/jama.288.7.862View ArticlePubMedGoogle Scholar
  3. MacLaren R, Jung R: Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy 2002, 22: 1140-1156. 10.1592/phco.22.13.1140.33519View ArticlePubMedGoogle Scholar
  4. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32: 858-873. 10.1097/01.CCM.0000117317.18092.E4View ArticlePubMedGoogle Scholar
  5. Cavaliere F, Masieri S, Annetta G, Gargano F, Proietti R: New indications for corticosteroids in intensive care units. Curr Drug Targets 2004, 5: 411-417. 10.2174/1389450043345362View ArticlePubMedGoogle Scholar
  6. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, et al.: Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004, 364: 1321-1328. 10.1016/S0140-6736(04)17188-2View ArticlePubMedGoogle Scholar
  7. Rady MY, Johnson DJ, Patel B, Larson J, Helmers R: Cortisol levels and corticosteroid administration fail to predict mortality in critical illness: the confounding effects of organ dysfunction and sex. Arch Surg 2005, 140: 661-668. 10.1001/archsurg.140.7.661View ArticlePubMedGoogle Scholar
  8. The National Heart LaBIARDSCTN: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006, 354: 1671-1684. 10.1056/NEJMoa051693View ArticleGoogle Scholar
  9. Barshes NR, Goodpastor SE, Goss JA: Pharmacologic immunosuppression. Front Biosci 2004, 9: 411-420.View ArticlePubMedGoogle Scholar
  10. Offermann G: Immunosuppression for long-term maintenance of renal allograft function. Drugs 2004, 64: 1325-1338. 10.2165/00003495-200464120-00005View ArticlePubMedGoogle Scholar
  11. Vidhun JR, Sarwal MM: Corticosteroid avoidance in pediatric renal transplantation: can it be achieved? Paediatr Drugs 2004, 6: 273-287. 10.2165/00148581-200406050-00002View ArticlePubMedGoogle Scholar
  12. Egidi FM: Management of hyperglycaemia after pancreastransplantation: are new immunosuppressants the answer? Drugs 2005, 65: 153-166. 10.2165/00003495-200565020-00001View ArticlePubMedGoogle Scholar
  13. Choy EH, Scott DL: Drug treatment of rheumatic diseasesin the 1990s. Achievements and future developments. Drugs 1997, 53: 337-348.View ArticlePubMedGoogle Scholar
  14. Criscione LG, St Clair EW: Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002, 14: 204-211. 10.1097/00002281-200205000-00002View ArticlePubMedGoogle Scholar
  15. Stokes DG, Kremer JM: Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 2003, 33: 1-18. 10.1053/sarh.2003.50022View ArticlePubMedGoogle Scholar
  16. Botsios C: Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005, 4: 162-170. 10.1016/j.autrev.2004.09.001View ArticlePubMedGoogle Scholar
  17. Rady MY, Johnson DJ: Hospital discharge to care facility: a patient-centered outcome for the evaluation of intensive care for octogenarians. Chest 2004, 126: 1583-1591. 10.1378/chest.126.5.1583View ArticlePubMedGoogle Scholar
  18. Romano PS, Roos LL, Jollis JG: Adapting a clinical co-morbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993, 46: 1075-1079. 10.1016/0895-4356(93)90103-8View ArticlePubMedGoogle Scholar
  19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22: 707-710.View ArticlePubMedGoogle Scholar
  20. Junger A, Engel J, Benson M, Bottger S, Grabow C, Hartmann B, Michel A, Rohrig R, Marquardt K, Hempelmann G: Discriminative power on mortality of a modified Sequential Organ Failure Assessment score for complete automatic computation in an operative intensive care unit. Crit Care Med 2002, 30: 338-342. 10.1097/00003246-200202000-00012View ArticlePubMedGoogle Scholar
  21. Rivers EP, Blake HC, Dereczyk B, Ressler JA, Talos EL, Patel R, Smithline HA, Rady MY, Wortsman J: Adrenal dysfunction in hemodynamically unstable patients in the emergency department. Acad Emerg Med 1999, 6: 626-630.View ArticlePubMedGoogle Scholar
  22. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283: 1038-1045. 10.1001/jama.283.8.1038View ArticlePubMedGoogle Scholar
  23. Alvarez-Lerma F, Palomar M, Leon C, Olaechea P, Cerda E, Bermejo B, Grupo de Estudio de Infecion F: Fungal colonization and/or infection in intensive care units. Multicenter study of 1,562 patients. Med Clin (Barc) 2003, 121: 161-166. 10.1157/13049416View ArticleGoogle Scholar
  24. Roman-Marchant O, Orellana-Jimenez CE, De Backer D, Melot C, Vincent JL: Septic shock of early or late onset: does it matter? Chest 2004, 126: 173-178. 10.1378/chest.126.1.173View ArticlePubMedGoogle Scholar
  25. de Gans J, van de Beek D, the European Dexamethasone in Adulthood Bacterial Meningitis Study I: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347: 1549-1556. 10.1056/NEJMoa021334View ArticlePubMedGoogle Scholar
  26. Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA: Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005, 80: 1558-1567.View ArticlePubMedGoogle Scholar
  27. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345: 1359-1367. 10.1056/NEJMoa011300View ArticlePubMedGoogle Scholar
  28. Finney SJ, Zekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients. JAMA 2003, 290: 2041-2047. 10.1001/jama.290.15.2041View ArticlePubMedGoogle Scholar
  29. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, Cerf C, Renaud E, Mesrati F, Carlet J, et al.: Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002, 288: 2859-2867. 10.1001/jama.288.22.2859View ArticlePubMedGoogle Scholar
  30. Amaya-Villar R, Garnacho-Montero J, Garcia-Garmendia JL, Madrazo-Osuna J, Garnacho-Montero MC, Luque R, Ortiz-Leyba C: Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2005, 31: 157-161. 10.1007/s00134-004-2509-9View ArticlePubMedGoogle Scholar
  31. Hanson P, Dive A, Brucher JM, Bisteau M, Dangoisse M, Deltombe T: Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20: 1371-1380. 10.1002/(SICI)1097-4598(199711)20:11<1371::AID-MUS4>3.0.CO;2-7View ArticlePubMedGoogle Scholar
  32. Behbehani NA, Al-Mane F, D'Yachkova Y, Pare P, FitzGerald JM: Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids [see comment]. Chest 1999, 115: 1627-1631. 10.1378/chest.115.6.1627View ArticlePubMedGoogle Scholar
  33. Lacomis D: Critical illness myopathy. Curr Rheumatol Rep 2002, 4: 403-408.View ArticlePubMedGoogle Scholar
  34. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, et al.: One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003, 348: 683-693. 10.1056/NEJMoa022450View ArticlePubMedGoogle Scholar
  35. Fletcher S, Kennedy D, Ghosh I, Misra V, Kiff K, Coakley J, Hinds C: Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003, 31: 1012-1016. 10.1097/01.CCM.0000053651.38421.D9View ArticlePubMedGoogle Scholar

Copyright

© Rady et al.; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.